NasdaqCM - Nasdaq Real Time Price USD

Intelligent Bio Solutions Inc. (INBS)

1.2800

-0.0800

(-5.88%)

At close: 4:00:00 PM EDT

1.2800

0.00

(0.00%)

After hours: 4:58:47 PM EDT

Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System

Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets Latin American drug screening market projected to reach USD 1.1 billion by 2030 Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technolog

GlobeNewswire 13 days ago

INBS
-5.88%
Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System

Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goals Drug Screening Reader - Arabic INBS' Drug Screening System now supports the Arabic language. NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to

GlobeNewswire last month

INBS
-5.88%
Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation as a gold sponsor at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference and Trade Show, taking place from April 1 – 4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions, will present at th

GlobeNewswire last month

INBS
-5.88%
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win

INBS secures a key U.S. patent, strengthening its IP protection and paving the way for 2025 market entry with innovative biometric technology.

Zacks last month

INBS
-5.88%

BSX

CAH
Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra

INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded access to its fingerprint drug testing in Spain and Andorra through a st

GlobeNewswire last month

INBS
-5.88%
US patent granted for INBS’ fingerprint drug screening technology

The patent is crucial for the company's testing system, which detects drugs in fingerprint sweat utilising lateral flow technology.

Medical Device Network last month

INBS
-5.88%
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry

Company’s 6th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology Patent protection strengthens Company’s competitive position as it prepares for planned entry into multi-billion dollar U.S. market in 2025 NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that the Company has been

GlobeNewswire last month

INBS
-5.88%
Intelligent Bio Solutions’ FDA Clearance Process Remains on Track for 2025 U.S. Launch

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided shareholders with a status update on the FDA clearance process for its Intelligent Fingerprint Drug Screening System, which remains on track for launch in the U.S. in 2025 targeting its opiate test system for codeine, as validated in the Company’s Pharmacokinetic (PK) study.

GlobeNewswire last month

INBS
-5.88%
EXCLUSIVE: FDA Seeks Additional Information For Intelligent Bio Solutions' Drug Screening System, Clearance Process Remains on Track For 2025 US Launch

On Tuesday, Intelligent Bio Solutions Inc. (NASDAQ:INBS) provided a status update on the FDA clearance process for its Intelligent Fingerprint Drug Screening System, which remains on track for launch in the U.S. in 2025, targeting its opiate test system for codeine. In December 2024, the company submitted its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review and clearance of its Intelligent Fingerprinting Drug Screening System. The FDA has reviewed and issue

Benzinga last month

INBS
-5.88%
iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025

RALEIGH, NC / ACCESS Newswire / March 21, 2025 /iAccess Alpha's Virtual Best Ideas Spring Investment Conference will take place on March 25-26, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and ...

ACCESS Newswire last month

ACCS

BCHT

IDN
Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it expects to receive its sixth patent in the United States, which will strengthen the protection of the lateral flow technology core to its Intelligent Fingerprinting Drug Testing Solution. This expected patent will enhance INBS’ existing intellectual property portfol

GlobeNewswire last month

INBS
-5.88%
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025 on March 25 and 26, 2025. iAccess Alpha Virtual Conference Details:Date: March 25-26, 2025Presentation Day and Time: Tuesday, March 25th at 11:00 a.m. ETWebcast: https:/

GlobeNewswire last month

INBS
-5.88%
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares of Common Stock

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced underwritten public offering of 1,500,000 shares of common stock at a public offering price of $2.00 per share of common stock, which included the full exercise of the underwriter’s option to purchase up to 195,652 additional shares of common st

GlobeNewswire 2 months ago

INBS
-5.88%
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of its previously announced underwritten public offering of 1,304,348 shares of common stock at a public offering price of $2.00 per share of common stock, for gross proceeds of approximately $2.6 million, before deducting underwriting discounts and commissions and offerin

GlobeNewswire 2 months ago

INBS
-5.88%
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may

GlobeNewswire 2 months ago

INBS
-5.88%
Intelligent Bio Solutions Second Quarter 2025 Earnings: US$0.50 loss per share (vs US$2.07 loss in 2Q 2024)

Intelligent Bio Solutions ( NASDAQ:INBS ) Second Quarter 2025 Results Key Financial Results Revenue: US$607.5k (down...

Simply Wall St. 2 months ago

INBS
-5.88%
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements

Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS)

GlobeNewswire 2 months ago

INBS
-5.88%
Intelligent Bio releases shareholder letter on 2024 growth, 2025 strategy

Intelligent Bio Solutions (INBS) issued a letter to shareholders from Harry Simeonidis, President and CEO, reflecting on a year of growth in 2024 and its strategic path forward into the multi-billion dollar U.S. market in 2025. “As we begin 2025, I wanted to take the opportunity to recap on the progress we made in 2024 and key upcoming catalysts including our planned entrance into the multi-billion dollar U.S. market… We believe the potential total addressable market in the U.S. for our Intellig

TipRanks 2 months ago

INBS
-5.88%
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy

Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today issued a letter to shareholders from Harry Simeonidis, President and CEO, reflecting on a year of growth in 2024 and its strategic path forward into the multi-billion dollar

GlobeNewswire 2 months ago

INBS
-5.88%
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch

Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S. expansion in 2025 following FDA 510(k) submission UK drug testing market projected to hit $453M by 2030, positioning INBS as a scalable, cost-effective industry leader NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology

GlobeNewswire 2 months ago

INBS
-5.88%

Performance Overview

Return	INBS	S&P 500 (^GSPC)
YTD	-8.57%	-3.93%
1-Year	-50.00%	+10.19%
3-Year	-99.14%	+36.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Intelligent Bio Solutions Inc. (INBS)

Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System

Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System

Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show

Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win

Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra

US patent granted for INBS’ fingerprint drug screening technology

Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry

Intelligent Bio Solutions’ FDA Clearance Process Remains on Track for 2025 U.S. Launch

EXCLUSIVE: FDA Seeks Additional Information For Intelligent Bio Solutions' Drug Screening System, Clearance Process Remains on Track For 2025 US Launch

iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025

Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant

Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares of Common Stock

Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock

Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock

Intelligent Bio Solutions Second Quarter 2025 Earnings: US$0.50 loss per share (vs US$2.07 loss in 2Q 2024)

Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements

Intelligent Bio releases shareholder letter on 2024 growth, 2025 strategy

Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy

Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch

Performance Overview